RougeTx raises $58 million in Series A financing to advance RTX-001, a potential oral treatment targeting vascular instability in HHT.
Written By: Kalyani Boharapi, M. Pharm (QA)
Reviewed By: Pharmacally Editorial Team
Preclinical biotechnology company RougeTx has launched with a $58 million Series A financing to advance its lead small-molecule candidate, RTX-001, toward first-in-human clinical development for hereditary hemorrhagic telangiectasia (HHT).
The financing was co-led by BioGeneration Ventures (BGV), Angelini Ventures, and Kurma Partners, with participation from the European Investment Bank’s Aurea co-investment facility, Epidarex Capital, Vesalius Biocapital Partners, ROM Utrecht Region, p53 Invest, and Kerna Ventures. RougeTx will use the proceeds to advance RTX-001 toward clinical development.
Targeting Vascular Instability in HHT
HHT is an inherited vascular disorder characterized by abnormal blood vessel formation, including arteriovenous malformations (AVMs). These fragile vessels can cause recurrent nosebleeds and gastrointestinal bleeding, leading to iron deficiency and chronic anemia. AVMs can also affect organs such as the lungs, liver, and brain, creating potentially serious complications.
RougeTx is developing RTX-001 to restore vascular stability by addressing dysfunction in pericytes, the mural cells that support and stabilize blood vessels. Preclinical data indicate that the candidate can restore pericyte attachment and strengthen fragile vascular structures.
HHT currently has no approved disease-modifying therapies that target the underlying vascular pathology. Management therefore relies largely on supportive care and off-label treatments.
RTX-001 Remains in Preclinical Development
RTX-001 has not yet entered human clinical trials, and RougeTx has not reported clinical efficacy, safety, dosing, or tolerability data. The company has not disclosed the design, patient population, endpoints, or timing of its planned first-in-human study.
The next development milestone will be progression of RTX-001 into clinical testing. If the candidate demonstrates sufficient safety and biological activity in humans, it could offer a disease-modifying approach for HHT by addressing vascular instability rather than treating bleeding complications alone.
periSCOPE Platform Extends Beyond HHT
RougeTx is also advancing its periSCOPE platform to identify additional small-molecule therapies for vascular diseases associated with vascular instability.
The platform builds on more than two decades of research into pericyte biology and vascular integrity by co-founder and scientific advisor Franck Lebrin, including work at Inserm and Leiden University Medical Center. RougeTx intends to use this biological foundation to expand its pipeline beyond HHT.
CEO Andrew Lightfoot said the preclinical data generated for RTX-001 provide a foundation for advancing the program toward clinical development, while the new financing will allow the company to investigate the same biology across other vascular disorders.
Representatives from BGV, Angelini Ventures, Kurma Partners, Epidarex Capital, and Vesalius Biocapital Partners will join RougeTx’s board of directors following the financing.
Reference
RougeTx Launches with $58 Million Series A Financing to Advance First-in-Class Treatment for Hereditary Hemorrhagic Telangiectasia, RougeTx, 06 October 2026
About the Writer
Kalyani Boharapi (LinkedIn) is a pharmacy professional and healthcare writer currently pursuing an M.Pharm in Regulatory Affairs at Dr. D. Y. Patil College of Pharmacy, with interests in pharmaceutical regulations, drug development, and healthcare innovation. She has academic exposure to dossier preparation, scientific writing, and regulatory documentation. Kalyani has also completed certification courses in Generative AI, AI in Pharma, and Bioinformatics, and actively participates in pharmaceutical conferences to stay updated with emerging trends and advancements in the healthcare and pharmaceutical industry.